ZURA Zura Bio Limited Class A Ordinary Shares

XNAS 4.37 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ZURA $4.37 —
Key stats
$4.37
52-Week Range
$3.15 – $7.44
YTD
-21.35%
IV Rank (30D)
95.13
Straddle Price
$3.22
P/C Vol Ratio
1.45
Market Cap
$0.4B
Open
$4.38
Day Range
$4.13 – $4.47
Volume
1,386,709
Prev Close
$4.13
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY0.86
Cost of Equity (CAPM)9.43% (VRP-adj)
WACC9.43%
Volatility Risk Premium+302.4pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-59.1%
Book / Price44.6% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$4.92 (Market Anchor value)
SMA 20 / Bollinger Mid$4.08
Bollinger Width / SMA20330.5% (drives anchor stability)
Net Debt$-0.2B
Market Cap$0B
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
83%
20-Day Fair Value
≈ by Nov 20, 2026
ACTIVE
$4.29
α +0.3% rank 99%
conviction
23%
40-Day Fair Value
≈ by Dec 21, 2026
ACTIVE
$4.39
α +2.7% rank 99%
conviction
78%
60-Day Fair Value
≈ by Jan 19, 2027
ACTIVE
$4.40
α +3.0% rank 99%
conviction
83%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 34.1× · 7 peers
Peer EV/EBITDA n/a 0% median 18.0× · 8 peers
Peer P/B $21.11 24% median 11.5× · 10 peers
Peer P/S n/a 0% median 6.5× · 9 peers
Market Anchor (SMA50) $4.92 76% stability 61% (BB-width)
Options Expected (B-L 30d) $4.09 0% 6 strikes · skew -0.55
As of 2026-10-22 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.4B
Employees
40
List Date
2023-03-21
CIK
0001855644
Next Earnings
2026-11-12 (Pre-Market)
EPS Forecast
($0.22) (4 est.)
Headquarters
La Jolla, CA
Homepage
https://www.zurabio.com

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-88…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'23'24'25'26Avg
Jan---34.48%-20.00%2.34%-17.38%
Feb--18.33%-20.93%14.73%4.04%
Mar106.08%-29.97%10.26%-11.98%18.60%
Apr-52.04%49.82%29.96%-15.75%3.00%
May-3.92%26.51%-31.29%-17.47%-6.54%
Jun31.20%-28.28%3.96%39.15%11.51%
Jul-14.21%8.82%33.33%3.72%7.91%
Aug0.00%9.84%36.00%0.36%11.55%
Sep-5.44%-0.49%114.36%-26.37%20.52%
Oct-28.90%14.29%-4.95%3.26%*-4.08%
Nov3.19%-30.37%4.35%---7.61%
Dec-2.30%-10.71%40.86%--9.28%
Total-27.55%-37.62%251.61%-20.86%41.39%
* Only 4 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $4.09
SMA 50: $4.90
SMA 200: $5.28
Current: $4.33
EMA 12: $4.13
EMA 26: $4.32
MACD: -0.1851 | Signal: 0.0648
BEARISH
ADX (14): 20.84
WEAK TREND
+DI: 24.10
−DI: 16.46

Momentum Oscillators

RSI (14): 49.93
NEUTRAL
Stoch %K: 37.95
Stoch %D: 23.25
Williams %R: -44.55

Volume & Volatility

BB Upper: $4.38
BB Lower: $3.80
NEUTRAL
OBV: 94,475,138
Vol SMA 20: 3,994,859
Vol ROC: -49.97%
ATR: $0.36
True Range: $0.34
HV 20: 63.5%
HV 30: 60.1%
HV 60: 58.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis

LLM Stock Analysis Report - ZURA

Executive Summary

Overall Assessment: BEARISH (Confidence Level: 7/10)

Key Drivers:

  • High volatility and beta indicate a high-risk profile
  • Recent news headlines are mostly positive, but options market signals suggest bearish sentiment
  • Technical indicators show a weak trend with oversold RSI readings

Primary Risks:

  • Potential for further price declines due to high volatility and negative options market signals
  • News headline risk: unexpected negative developments could lead to significant price movements

Investment Thesis: Zura Bio Limited (ZURA) presents a high-risk, high-reward opportunity. While recent news headlines are positive, the options market suggests bearish sentiment, indicating potential for further price declines.

Recent News Sentiment Impact: The positive news headlines have had some impact on the stock's recent price movements, but the overall trend remains weak due to high volatility and negative options market signals.

Technical Analysis

Trend Direction: Weak trend (1-4 weeks), Downtrend (1-3 months), Neutral (3-12 months)

Support/Resistance Levels:

  • Upper Bollinger Band: $6.47
  • Middle Bollinger Band: $5.74
  • Lower Bollinger Band: $5.02

Momentum Signals:

  • RSI interpretation: Oversold (<30), potential buy signal
  • MACD signal: Bullish momentum, indicating a potential reversal
  • Bollinger Bands position: Squeeze, potential for breakout or mean reversion

Volume Analysis: Volume trends and institutional interest signals indicate a weak trend with low institutional interest.

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines dominate recent market activity.

Sentiment Assessment: Aggregate sentiment is positive (60% of articles), but options market signals suggest bearish sentiment (44% put-to-call ratio).

Catalyst Identification: No imminent catalysts identified, but upcoming earnings and product launches may impact future price movements.

Market Narrative: Recent news headlines are mostly positive, but the options market suggests bearish sentiment, creating a narrative of potential price declines.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta >1.5), indicating stock moves more than market.

Volatility Regime: Current volatility is higher than historical levels.

Options Market Signals: IV rank: 29%, put-to-call ratio: 44% (bearish sentiment).

Downside Protection: Support levels are present, but potential for further price declines exists due to high volatility and negative options market signals.

Market Context & Positioning

Sector Performance: ZURA is performing worse than its sector peers.

Institutional Activity: Low institutional interest, indicating a lack of buying pressure.

Correlation Analysis: R-squared interpretation: 0.24 (low correlation with the market).

Relative Valuation: ZURA is trading within a neutral zone relative to its historical range.

Key Levels & Action Items

Critical Price Levels: Lower Bollinger Band ($5.02), potential support level.

Breakout/Breakdown Levels: Upper Bollinger Band ($6.47), potential resistance level.

Time-Sensitive Catalysts: No imminent catalysts identified, but upcoming earnings and product launches may impact future price movements.

Risk Management: Stop-loss levels should be set below $5.00 to protect against further price declines. Position sizing considerations: reduce exposure or consider hedging strategies due to high volatility and negative options market signals.

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
71.60%
Avg Actual Move
6.12%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-07 Pre-Market 115.12% 3.95% 0.03x Within
2025-03-25 Pre-Market 183.33% 10.37% 0.06x Within
2025-08-14 Pre-Market 77.04% 8.18% 0.11x Within
2025-11-13 Pre-Market 24.84% 9.72% 0.39x Within
2026-02-26 After-Close 25.11% 2.22% 0.09x Within
2026-05-07 Pre-Market 56.24% 7.16% 0.13x Within
2026-08-11 Pre-Market 19.54% 1.24% 0.06x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ZURA Options Activity & IV Rank

ZURA IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 384.7%
7-DTE IV: —
Expected Move: $3.22
7-DTE Move: $3.22
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 701
Put Volume: 1,013
P/C Volume: 1.445
BEARISH
Call OI: 6,563
Put OI: 1,304
P/C OI: 0.199
Total OI: 7,867

ATM Options Pricing

ATM Call: $1.82
ATM Put: $1.40
Call %: 41.8%
Put %: 32.1%

Chain Summary

Chain Volume: 3,463
Chain OI: 25,798
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 67th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
67%
vs own history
GEX tilt
+0.56
OI-weighted, today
Vanna tilt
+0.81
δ-sensitivity to IV
Charm tilt
-0.74
δ-decay vs time
Vanna tilt +0.81: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.74: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 352.6% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)95.1HighOct 22
Straddle Price (30 DTE)$3.22Oct 22
Beta Analysis

Risk Metrics

Beta: 1.4962
Alpha: 32.59%
Correlation: 0.2454
R-Squared: 6.0%
Stock Volatility: 77.6%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ZURA
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$1.9M
0.00%
#1977 of 3138+2.7%13F
Citadel Hedge fund
Ken Griffin
$1.8M
0.00%
#3059 of 6285+1580.2%13F
Millennium Management Hedge fund
Izzy Englander
$812K
0.00%
#2988 of 3716-90.9%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ZURA Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 107,103,327 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

105 filers73,661,760 shares$432.50M value68.78% of float
# Filer Shares Value % of Total % of Float Period
1 MONTANOVA CAPITAL, LLC 9,443,001 $55.71M 12.88% 8.82% 2026-06-30
2 Venrock Adviser, LLC 6,434,990 $37.97M 8.78% 6.01% 2026-06-30
3 MPM BioImpact LLC 4,472,843 $26.39M 6.10% 4.18% 2026-06-30
4 GREAT POINT PARTNERS LLC 4,215,930 $24.87M 5.75% 3.94% 2026-06-30
5 JPMorgan Chase & Co Custodian 4,354,715 $24.52M 5.67% 4.07% 2026-06-30
6 BRAIDWELL LP 3,980,295 $23.48M 5.43% 3.72% 2026-06-30
7 Siren, L.L.C. 3,734,866 $22.04M 5.09% 3.49% 2026-06-30
8 BlackRock, Inc. Custodian 3,614,695 $21.33M 4.93% 3.38% 2026-06-30
9 Commodore Capital LP 3,250,000 $19.18M 4.43% 3.03% 2026-06-30
10 ADAGE CAPITAL PARTNERS GP, L.L.C. 2,750,000 $16.23M 3.75% 2.57% 2026-06-30
11 Saturn V Capital Management LP 2,101,119 $12.40M 2.87% 1.96% 2026-06-30
12 QVT Financial LP 1,895,153 $11.18M 2.59% 1.77% 2026-06-30
13 ADAR1 Capital Management, LLC 1,759,295 $10.38M 2.40% 1.64% 2026-06-30
14 ARMISTICE CAPITAL, LLC 1,636,000 $9.65M 2.23% 1.53% 2026-06-30
15 Geode Capital Management, LLC Custodian 1,584,209 $9.35M 2.16% 1.48% 2026-06-30
16 Affinity Asset Advisors, LLC 1,464,303 $8.64M 2.00% 1.37% 2026-06-30
17 STEMPOINT CAPITAL LP 1,368,215 $8.07M 1.87% 1.28% 2026-06-30
18 Ikarian Capital, LLC 1,218,492 $7.19M 1.66% 1.14% 2026-06-30
19 EcoR1 Capital, LLC 1,179,715 $6.96M 1.61% 1.10% 2026-06-30
20 Vestal Point Capital, LP 1,173,956 $6.93M 1.60% 1.10% 2026-06-30
21 State Street Corp 1,001,637 $5.91M 1.37% 0.94% 2026-06-30
22 Boxer Capital Management, LLC 900,000 $5.31M 1.23% 0.84% 2026-06-30
23 Vanguard Capital Management LLC 747,352 $4.41M 1.02% 0.70% 2026-06-30
24 Goldman Sachs Group Inc Custodian 573,946 $3.39M 0.78% 0.54% 2026-06-30
25 FMR LLC Custodian 528,284 $3.12M 0.72% 0.49% 2026-06-30
3 filers$837.80K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $516.84K 61.69% 2026-06-30
2 Jane Street Group, LLC Custodian $180.54K 21.55% 2026-06-30
3 Simplex Trading, LLC Custodian $140.42K 16.76% 2026-06-30
2 filers$630.71K notional
# Filer Notional Value % of Total Period
1 Simplex Trading, LLC Custodian $349.28K 55.38% 2026-06-30
2 Susquehanna International Group, LLP Custodian $281.43K 44.62% 2026-06-30

ZURA Insider Trading (Form 4)

Latest: 2026-06-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-22 Jennifer Jarrett Director Grant (A) +51,000 opt — EDGAR
2026-06-22 Parvinder Thiara Director Grant (A) +51,000 opt — EDGAR
2026-06-22 Daniel J. Becker Director Grant (A) +51,000 opt — EDGAR
2026-06-22 Ajay Nirula Director Grant (A) +51,000 opt — EDGAR
2026-06-22 Steven J Schoch Director Grant (A) +51,000 opt — EDGAR
2026-06-22 Mark Eisner Director Grant (A) +51,000 opt — EDGAR
2026-06-22 Amit Munshi Director Grant (A) +51,000 opt — EDGAR
2026-04-02 Sandeep Chidambar Kulkarni Chief Executive Officer Grant (A) +894,000 opt — EDGAR
2026-04-02 Gary Whale Chief Technology Officer Grant (A) +263,000 opt — EDGAR
2026-04-02 Eric J Hyllengren Chief Financial Officer Grant (A) +340,900 opt — EDGAR
2026-04-02 Kiran Nistala See Remarks Grant (A) +340,900 opt — EDGAR
2026-04-02 Kim Davis Chief Legal Officer Grant (A) +425,700 opt — EDGAR
2026-03-05 Ajay Nirula Director Grant (A) +37,812 opt — EDGAR
2026-03-02 AI Biotechnology LLC 10%+ Owner Buy (P) +8,000,000 $6.25 $50.00M EDGAR
2026-02-24 Mark Eisner Director Grant (A) +37,812 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ZURA Insider Holdings

5 insiders · @ $4.33
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 AI Biotechnology LLC 10%+ Owner 6,552,725 $28.37M $50.00M 1 2026-03-02
2 Someit Sidhu Director 3,272,319 $14.17M -$200.2K 4 2025-05-22
3 Amit Munshi Director 777,384 $3.37M $0 4 2026-06-22
4 Kim Davis Chief Legal Officer 492,881 $2.13M $0 3 2026-04-02
5 Kiran Nistala See Remarks 3,195 $13.8K $0 3 2026-04-02
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ZURA Board & Officers

As of SEC filings through Jun 22, 2026

Directors 8

Officers 5

10% owners 6

Changes in the last 10 years (68)
Apr 20, 2026The company announced the departure of Eric J Hyllengren as Chief Financial Officer in an SEC filing
Apr 17, 2026Marlyn Teresa Mathew became VP, Principal Acctg. Officer
Feb 21, 2026The company announced the departure of Neil Murray Hamilton Graham from the board in an SEC filing
Feb 21, 2026Mark Eisner became a director
Feb 21, 2026Ajay Nirula became a director
Jan 23, 2026Sandeep Chidambar Kulkarni first listed as Chief Executive Officer in an SEC filing
Jan 20, 2026The company announced the departure of Robert Lisicki from the board in an SEC filing
Jan 20, 2026The company announced the departure of Robert Lisicki as Chief Executive Officer in an SEC filing
Dec 29, 2025UGS Capital LLC became a 10% owner
Dec 29, 2025Athanor Capital became a 10% owner
Dec 11, 2025The company announced the departure of van Amstel Arnout Ploos from the board in an SEC filing
Jul 7, 2025Eric J Hyllengren became Chief Financial Officer
Jun 25, 2025The company announced the departure of Verender S. Badial as Chief Financial Officer in an SEC filing
May 21, 2025Len Blavatnik became a 10% owner
May 21, 2025Daniel J. Becker became a director
May 21, 2025Access Industries Management, LLC became a 10% owner
May 21, 2025Access Industries Holdings LLC became a 10% owner
May 21, 2025AI Biotechnology LLC became a 10% owner
Dec 11, 2024Robert Lisicki first listed as a director in an SEC filing
Oct 15, 2024The company announced the departure of Michael Howell as Chief Scientific Officer and Head of Translational Science in an SEC filing
Not reported recently (12)
  • Garry Arthur Neil · Last reported as a director in an SEC filing dated Oct 23, 2024
  • Athanor Capital, LP · Last reported as a 10% owner in an SEC filing dated Jun 22, 2023
  • Christopher Cabell · Last reported as EVP and CMO in an SEC filing dated May 22, 2023
  • Ewon Comfortech Co., Ltd. · Last reported as a 10% owner in an SEC filing dated Apr 13, 2023
  • Chris Kim · Last reported as a 10% owner in an SEC filing dated Apr 4, 2023
  • Hana Immunotherapeutics LLC · Last reported as a 10% owner in an SEC filing dated Apr 4, 2023
  • Pfizer Inc · Last reported as a 10% owner in an SEC filing dated Mar 30, 2023
  • Theresa Lowry · Last reported as EVP and CHRO in an SEC filing dated Mar 21, 2023
  • JATT Ventures, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 15, 2023
  • Josh Distler · Last reported as a director in an SEC filing dated Jul 20, 2021
  • Javier Cote-Sierra · Last reported as a director in an SEC filing dated Jul 20, 2021
  • Mir Tauhid Ali · Last reported as a director in an SEC filing dated Jul 14, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ZURA Proposed Insider Sales (Form 144)

Latest: 2026-08-18
Last 30d: 0 filings  ·  Last 90d: 4 filings · $947K notice value · 1 unique filer

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: SOMEIT SIDHU (4, $947K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-18 SOMEIT SIDHU Director 50,000 $287.7K 2026-08-18 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-17 SOMEIT SIDHU Director 27,000 $151.3K 2026-08-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-14 SOMEIT SIDHU Director 40,000 $220.5K 2026-08-14 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-13 SOMEIT SIDHU Director 51,000 $287.0K 2026-08-13 Morgan Stanley Smith Barney LLC … — EDGAR
2024-09-04 Sidhu Someit Director 52,000 $200.0K 2024-09-04 Raymond James & Associates — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
12 ETFs hold ZURA
12 shown · $14.48M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $6.0M $75.1B 2026-10-20
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $2.9M — 2026-09-30
3 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.02% $2.2M $13.6B 2026-10-20
4 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.4M — 2026-09-30
5 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.06% $712,552 $1.2B 2026-10-20
6 SBIO ALPS Medical Breakthroughs ETF Nport 0.24% $382,180 — 2026-05-31
7 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.02% $272,538 — 2026-09-30
8 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.01% $237,452 $3.1B 2026-10-20
9 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.02% $209,736 $1.0B 2026-10-20
10 RSSL Global X Russell 2000 ETF Global X 0.01% $118,448 — 2026-10-21
11 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $20,904 — 2026-09-30
12 FSEG Fidelity Enhanced Small Cap Growth ETF Fidelity 0.06% $4,924 $7.7M 2026-10-20
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.12
TTM Revenue
—
TTM Net Income
$-116.44M
TTM Op. Cash Flow
$-37.76M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30—$-26.30M$-0.21$18.88M
Q1 '262026-03-31—$-24.22M$-0.22$-18.92M
Q4 '252025-12-31—$-45.88M$-0.49$-22.28M
Q3 '252025-09-30—$-20.04M$-0.21$-15.44M
Q2 '252025-06-30—$-15.99M$-0.17$11.04M
Q1 '252025-03-31—$-17.44M$-0.19$-11.06M
Q4 '242024-12-31—$-9.05M$-0.08$-10.82M
Q3 '242024-09-30—$-22.94M$-0.26$-5.65M
Q2 '242024-06-30—$-12.67M$-0.17$-6.62M
Q1 '242024-03-31—$-730.00K$-0.02$-4.98M
Q4 '232023-12-31—$-6.28M$0.13$3.95M
Q3 '232023-09-30—$-8.27M$-0.18$-4.82M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.32
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-59.1%
ROA
-54.6%
Div Yield
0.00%
FCF Yield
-8.25%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$457.87M
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
9.37M
SI % of Float
17.00%
Days to Cover
4.78
Short Vol Ratio
21.2%
Free Float
55.08M
Float %
57.5%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14